Evaluation of bivalirudin-based anticoagulation for extracorporeal membrane oxygenation, including patients with COVID-19
These results suggest that a standardized pharmacist-directed protocol for bivalirudin in ECMO achieves timely therapeutic anticoagulation levels. Patients with COVID-19 trended toward longer times to two consecutive therapeutic aPTTs. Further studies are needed to evaluate dosing strategies in patients with and without COVID-19.
Authors
- Casey Bardsley
- Chelsea Bast
- Hasan Sajid Kazmi (ORCID: https://orcid.org/0000-0003-0049-1228)
- David Sugrue (ORCID: https://orcid.org/0009-0009-5857-8001)
- Ashley Milkovits (ORCID: https://orcid.org/0000-0002-1188-8602)
- Miranda Raguindin
Institutions
- Hartford Hospital (US)
- Carilion Roanoke Memorial Hospital (US)
- Duke Raleigh Hospital (US)
- Regional Medical Center (US)
- Sentara Virginia Beach General Hospital (US)
Publication Details
- Journal
- Journal of ExtraCorporeal Technology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1051/ject/2025045
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00